On Monday, French drugmaker Sanofi SA said it would buy U.S. - based
hemophilia drugmaker Bioverativ Inc. for over $ 11.5 billion.
In the early hours of Monday morning, French drug giant Sanofi said it would buy
hemophilia drugmaker Bioverativ, a Biogen spinout that is less than a year old, for $ 11.6 billion.
Not exact matches
In January, Sanofi agreed to acquire Biogen's
hemophilia spinoff Bioverativ for $ 11.6 billion, and now the Japanese
drugmaker Takeda is bidding for the rare - disease
drugmaker Shire.